| Literature DB >> 32053069 |
Marco Calvinho Cavaco1, Javier Valle Garcia2, Ruben Diogo Marques da Silva3, João Domingos Galamba Correia3, Miguel Augusto Rico Botas Castanho1, David Andreu Martinez2, Vera Luísa Santos Neves1.
Abstract
The use of peptides as drug carriers across the blood-brain barrier (BBB) has increased significantly during the last decades. PepH3, a seven residue sequence (AGILKRW) derived from the α-helical domain of the dengue virus type-2 capsid protein, translocates across the BBB with very low toxicity. Somehow predictably from its size and sequence, PepH3 is degraded in serum relatively fast. Among strategies to increase peptide half-life (t1/2), use of the enantiomer (wholly made of D-amino acid residues) can be quite successful if the peptide interacts with a target in non-stereospecific fashion. Here we report that aGilkrw (DPepH3), the enantiomer of PepH3, has a much longer t1/2. We also confirm that BBB translocation is receptor-independent, which fully validates the enantiomer strategy chosen. Moreover, the cell internalization step that initiates transcytosis follows a macropinocytosis pathway. Taken together, our results place DPepH3 at the forefront of a second generation of BBB shuttles with excellent translocation and internalization properties, safety, and improved stability. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: Adsorption-mediated transcytosis; Blood-brain barrier; D-amino acids; Macropinocytosis; PepH3; Peptide shuttles; Stability
Year: 2020 PMID: 32053069 DOI: 10.2174/1381612826666200213094556
Source DB: PubMed Journal: Curr Pharm Des ISSN: 1381-6128 Impact factor: 3.116